Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome
Uloženo v:
| Název: | Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
|---|---|
| Autoři: | Elisabeth H. Adam, Benedikt Schmid, Michael Sonntagbauer, Peter Kranke, Kai Zacharowski, Patrick Meybohm |
| Zdroj: | Crit Care Critical Care, Vol 24, Iss 1, Pp 1-4 (2020) |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2020. |
| Rok vydání: | 2020 |
| Témata: | Immunomodulatory agents, Male, Critical Illness, Pneumonia, Viral, Comorbidity, Therapies, investigational, Fibrin Fibrinogen Degradation Products, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Pulmonary edema, Research Letter, Humans, Pandemics, Aged, Salvage Therapy, ddc:610, Respiratory distress syndrome, adult, Respiratory Distress Syndrome, RC86-88.9, SARS-CoV-2, COVID-19, Medical emergencies. Critical care. Intensive care. First aid, Middle Aged, Critical care, Pneumonia, Viral/therapy [MeSH], Aged [MeSH], Coronavirus Infections/therapy [MeSH], Fibrin Fibrinogen Degradation Products/therapeutic use [MeSH], Respiratory Distress Syndrome/virology [MeSH], Critical Illness/therapy [MeSH], Male [MeSH], COVID-19 [MeSH], Comorbidity [MeSH], SARS-CoV-2 [MeSH], Female [MeSH], Humans [MeSH], Salvage Therapy [MeSH], Middle Aged [MeSH], Pandemics [MeSH], Peptide Fragments/therapeutic use [MeSH], Respiratory Distress Syndrome/therapy [MeSH], Betacoronavirus [MeSH], Peptide Fragments, 3. Good health, Female, Coronavirus Infections |
| Popis: | Background!#!Myoglobin clearance in acute kidney injury requiring renal replacement therapy is important because myoglobin has direct renal toxic effects. Clinical data comparing different modalities of renal replacement therapy addressing myoglobin clearance are limited. This study aimed to compare two renal replacement modalities regarding myoglobin clearance.!##!Methods!#!In this prospective, randomized, single-blinded, single-center trial, 70 critically ill patients requiring renal replacement therapy were randomized 1:1 into an intervention arm using continuous veno-venous hemodialysis with high cutoff dialyzer and a control arm using continuous veno-venous hemodiafiltration postdilution with high-flux dialyzer. Regional citrate anticoagulation was used in both groups to maintain the extracorporeal circuit. The concentrations of myoglobin, urea, creatinine, β2-microglobulin, interleukin-6 and albumin were measured before and after the dialyzer at 1 h, 6 h, 12 h, 24 h and 48 h after initiating continuous renal replacement therapy.!##!Results!#!Thirty-three patients were allocated to the control arm (CVVHDF with high-flux dialyzer) and 35 patients to the intervention arm (CVVHD with high cutoff dialyzer). Myoglobin clearance, as a primary endpoint, was significantly better in the intervention arm than in the control arm throughout the whole study period. The clearance values for urea and creatinine were higher in the control arm. There was no measurable albumin clearance in both arms. The clearance data for β!##!Conclusions!#!Myoglobin clearance using continuous veno-venous hemodialysis with high cutoff dialyzer and regional citrate anticoagulation is better than that with continuous veno-venous hemodiafiltration with regional citrate anticoagulation.!##!Trial registration!#!German Clinical Trials Registry (DRKS00012407); date of registration 23/05/2017. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012407 . |
| Druh dokumentu: | Article Conference object Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1364-8535 |
| DOI: | 10.1186/s13054-020-03293-8 |
| Přístupová URL adresa: | https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-020-03293-8 https://pubmed.ncbi.nlm.nih.gov/32972429 https://doaj.org/article/953e989e67c74769b235ce902413a125 https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03293-8 https://europepmc.org/article/MED/32972429 https://pubmed.ncbi.nlm.nih.gov/32972429/ https://link.springer.com/content/pdf/10.1186/s13054-020-03293-8.pdf https://www.ncbi.nlm.nih.gov/pubmed/32972429 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512215 https://repository.publisso.de/resource/frl:6463097 |
| Rights: | CC BY |
| Přístupové číslo: | edsair.doi.dedup.....4f32ecb6ac425a9cd02e40c4c83e4daa |
| Databáze: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background!#!Myoglobin clearance in acute kidney injury requiring renal replacement therapy is important because myoglobin has direct renal toxic effects. Clinical data comparing different modalities of renal replacement therapy addressing myoglobin clearance are limited. This study aimed to compare two renal replacement modalities regarding myoglobin clearance.!##!Methods!#!In this prospective, randomized, single-blinded, single-center trial, 70 critically ill patients requiring renal replacement therapy were randomized 1:1 into an intervention arm using continuous veno-venous hemodialysis with high cutoff dialyzer and a control arm using continuous veno-venous hemodiafiltration postdilution with high-flux dialyzer. Regional citrate anticoagulation was used in both groups to maintain the extracorporeal circuit. The concentrations of myoglobin, urea, creatinine, β2-microglobulin, interleukin-6 and albumin were measured before and after the dialyzer at 1 h, 6 h, 12 h, 24 h and 48 h after initiating continuous renal replacement therapy.!##!Results!#!Thirty-three patients were allocated to the control arm (CVVHDF with high-flux dialyzer) and 35 patients to the intervention arm (CVVHD with high cutoff dialyzer). Myoglobin clearance, as a primary endpoint, was significantly better in the intervention arm than in the control arm throughout the whole study period. The clearance values for urea and creatinine were higher in the control arm. There was no measurable albumin clearance in both arms. The clearance data for β!##!Conclusions!#!Myoglobin clearance using continuous veno-venous hemodialysis with high cutoff dialyzer and regional citrate anticoagulation is better than that with continuous veno-venous hemodiafiltration with regional citrate anticoagulation.!##!Trial registration!#!German Clinical Trials Registry (DRKS00012407); date of registration 23/05/2017. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012407 . |
|---|---|
| ISSN: | 13648535 |
| DOI: | 10.1186/s13054-020-03293-8 |